Associated Genetic Biomarkers
Calreticulin (CALR) is a calcium-binding protein that functions in calcium storage and transcription regulation. Missense mutations, silent mutations, nonsense mutations, and frameshift insertions and deletions are observed in cancers such as colorectal cancer, leukemias, myeloproliferative neoplasms, and stomach cancer.
CALR is altered in 1.22% of all cancers with myeloproliferative neoplasm, high grade ovarian serous adenocarcinoma, lung adenocarcinoma, essential thrombocythemia, and breast invasive ductal carcinoma having the greatest prevalence of alterations .
The most common alterations in CALR are CALR Mutation (0.85%), CALR Amplification (0.33%), CALR L367fs (1.13%), CALR K385fs (0.53%), and CALR Loss (0.06%) .
CALR status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains CALR status as an inclusion criterion, 1 is phase 2 (0 open).
Trials with CALR status in the inclusion eligibility criteria most commonly target myelofibrosis .
The most frequent alteration to serve as an inclusion eligibility criterion is CALR Mutation .
Allogeneic hematopoietic stem cell transplantation, busulfan, cyclophosphamide, and fludarabine are the most frequent therapies in trials with CALR as an inclusion criteria .
Significance of CALR in Diseases
Multiple Myeloma +
Plasma Cell Leukemia +
CALR is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 0 are open and 1 is closed. Of the trial that contains CALR status and plasma cell leukemia as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.